Eliane Dias da Silva

Universidade Federal do Rio Grande do Sul | UFRGS · Departamento de Endocrinologia

Background: Gender dysphoria is defined as a feeling of distress resulting from the incongruence between the sex assigned at birth and the gender identity, lasting longer than 6 months. In individuals with gender dysphoria, gender-affirming hormone therapy (GAHT) may improve quality of life (QoL). Objectives: We aimed to assess perceived QoL, to co...

Background: Gender dysphoria is defined as a feeling of distress resulting from the incongruence between the gender assigned at birth and the identity gender and lasting longer than 6 months. In individuals with gender dysphoria, gender-affirming hormone therapy(GAHT) may improve quality of life (QoL). Objectives: Here, we aimed to assess perceived...

The effects of gluteal implants on bone mass remain unclear. Transgender women with ILS presented higher BMD in the hip compared with transgender women without implants, while no difference was observed in other sites. These results may be artifactual and suggest using spine/forearm sites for DXA in individuals with ILS. Purpose: The inappropriat...

Estrogen deficiency is classically associated with bone loss in both men and women. In transgender women, after being submitted to gender-affirming surgery (GAS), the main goal of hormone therapy (HT) is to maintain the female phenotype and prevent the consequences of the orchiectomy-related hypogonadal state. The aim of this study was to evaluate...

In transgender men (FtM), testosterone therapy may induce changes in different body compartments. The aim of this study was to evaluate body fat and muscle mass, visceral adipose tissue and bone mineral density in FtM transgender individuals receiving cross-sex hormone therapy (CSHT). Sixty two FtM were included in the protocol and performed labora...

Objective Cross‐sex hormone therapy (CSHT) has been associated with changes in bone and lean/fat mass. This study assessed BMD, appendicular lean mass (ALM), and total fat mass in transwomen undergoing CSHT. Patients and Design We evaluated 142 transwomen (mean age: 33.7±10.3 years; BMI: 25.4±4.6; 86.6% with previous CSHT) during the first three m...